Introduction: AUB (not otherwise specified) is a diagnosis that does not apply to menorrhagia only, but also includes (Menometrorrhagia) excessively prolonged and frequent bleeding.  Ormeloxifene (also known as centchroman) is a selective estrogen receptor modulators. This study was conducted to assess the efficacy, safety and compliance of Ormeloxifene in the medical management of abnormal uterine bleeding.

Methodology: This quasi experimental, one group pre and posttest research design study was conducted among 30 participants in a tertiary care institute in a metropolitan city during January 2016 – June 2017. Patients with AUB were administered with Ormeloxifene were advised to follow up one monthly for the first three months and then three monthly follow up for 6 months.

Results: The mean age of all the patients was 35.96 ± 5.62 years. There was statistically significant difference of mean hemoglobin, mean endometrial thickness and mean PABC score observed between pre-treatment and 3 months and 6 months of post treatment. Mean hemoglobin concentration was increased while mean endometrial thickness and mean PABC score was decreased as the duration of treatment was increased from 3 months to 6 months.

Conclusion: Ormeloxifene is quick acting, effective and appears to be a promising option for the medical management of DUB. It leads to a significant reduction in menstrual blood loss, a significant rise in hemoglobin concentration and a significant decrease in endometrial thickness with very minimal side effect.

 

Keywords: Dysfunctional uterine bleeding, Ormeloxifene, Pregnancy-associated breast cancer, Hemoglobin, Endometrial thickness